PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth above 1.5x AGEN's 6.86%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.23%
Operating income growth above 1.5x AGEN's 5.28%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
18.34%
Net income growth above 1.5x AGEN's 4.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.95%
EPS growth above 1.5x AGEN's 5.96%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
32.95%
Diluted EPS growth above 1.5x AGEN's 5.96%. David Dodd would see if there's a robust moat protecting these shareholder gains.
21.91%
Share count expansion well above AGEN's 1.07%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above AGEN's 1.07%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth above 1.5x AGEN's 1.07%. David Dodd would confirm a clear edge in underlying cash generation.
46.06%
FCF growth above 1.5x AGEN's 1.79%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
85.25%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
76.39%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
-13944.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
85.03%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
64.22%
3Y net income/share CAGR above 1.5x AGEN's 16.05%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
5293.49%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
188.65%
Positive 5Y equity/share CAGR while AGEN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
367.41%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Our R&D shrinks while AGEN invests at 23.59%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-22.47%
We cut SG&A while AGEN invests at 21.53%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.